Efficacy and safety of low-dose Interleukin-2 in the treatment of moderate to severe bullous pemphigoid: a single center perspective-controlled trial

Published: 16 August 2024| Version 1 | DOI: 10.17632/j29hrz5z7j.1
Contributor:
Ruzeng Xue

Description

Supplemental material for " Efficacy and safety of low-dose Interleukin-2 in the treatment of moderate to severe bullous pemphigoid: a single center perspective-controlled trial"

Files

Institutions

  • Southern Medical University

Categories

Interleukin, Bullous Disease

Licence